Ratio Therapeutics Inc.
PrivateLast Round
Series C
Jul 16, 2026
Total Funding Raised
$90M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Ratio Therapeutics Inc. operates in Healthcare & Life Sciences and is based in Boston, Massachusetts. Its latest recorded funding round was a Series B round in January 2024.
Ratio Therapeutics Inc. is a biotechnology company that develops next-generation precision radiopharmaceuticals for the treatment of solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials, Pharma Supply Chain
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ratio Therapeutics Inc. Comparables
Compare Ratio Therapeutics Inc. with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| ARTBIO | 92% | |
| Aktis Oncology | 89% | |
| Actithera | 87% |
For institutional investors. Book with your work email.
Ratio Therapeutics Inc. Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Jul 16, 2026 | ||||
| Series B | Jan 17, 2024 | ||||
| Series A | Feb 1, 2023 | ||||
| Seed | Jun 10, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Ratio Therapeutics Inc. Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Center for Technology Licensing at Cornell University | Series B |
| Duquesne Family Office | Series C, Series A |
| Pags Group | Series B |
| Charles and Lynn Schusterman Family Philanthropies | Series A |
| Schusterman Family Investments | Series A, Series B |
| Catalio Capital Management | Series A, Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 55% MoM, reaching 6.1K.
- Jul 24, 2026
Monthly visitors increased 37% MoM.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- partners_withSep 9, 2026
On Sep 9th '26, Ratio Therapeutics and RayzeBio, Inc. enter a research collaboration and license agreement to advance a novel radiopharmaceutical program focused on two undisclosed targets, with RayzeBio, Inc. holding an exclusive worldwide license to resulting candidates and products and assuming development, manufacturing, and commercialization responsibilities after specified research activities.
For institutional investors. Book with your work email.
Ratio Therapeutics Inc. Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Ratio Therapeutics Inc.'s valuation, stock price, and market status.
Is Ratio Therapeutics Inc. a public or private company?
Ratio Therapeutics Inc. is a private company.
What is the current stock price of Ratio Therapeutics Inc.?
Ratio Therapeutics Inc. is a private company, so its shares have no public market price. Caplight tracks Ratio Therapeutics Inc.'s secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Ratio Therapeutics Inc. worth (valuation)?
Valuation information for Ratio Therapeutics Inc. is not publicly available.
Can I buy Ratio Therapeutics Inc. stock?
Ratio Therapeutics Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Ratio Therapeutics Inc.'s last funding round?
Ratio Therapeutics Inc.'s most recent funding round was Series C on July 16, 2026.
Who are the main investors in Ratio Therapeutics Inc.?
Key investors in Ratio Therapeutics Inc. include Duquesne Family Office, Charles and Lynn Schusterman Family Philanthropies, Schusterman Family Investments.
Will Ratio Therapeutics Inc. IPO soon?
No public IPO plans have been announced for Ratio Therapeutics Inc..
How can I track Ratio Therapeutics Inc. secondary market activity?
Caplight tracks bids, offers, and trades in Ratio Therapeutics Inc.'s shares on secondary markets.